Vera Therapeutics, Inc. (VERA) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $72.00K; Additional Paid in Capital, Common StockUSD $1.40B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-403.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $72.00K; Additional Paid in Capital, Common StockUSD $1.38B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-156.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $71.00K; Additional Paid in Capital, Common StockUSD $1.36B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $786.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $64.00K; Additional Paid in Capital, Common StockUSD $1.07B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $881.00K.
Vera Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $72.00K | $1.40B | $-403.00K | $-991.37M | $407.76M | 3 month · $15.86M |
| 2026-03-31 | (m) | $72.00K | $1.38B | $-156.00K | $-881.90M | $499.70M | 3 month · $13.21M |
| 2025-12-31 | (m) | $71.00K | $1.36B | $786.00K | $-760.87M | $604.52M | 12 month · $37.93M |
| 2025-09-30 | $0.00 | $64.00K | $1.07B | $881.00K | $-669.77M | $398.88M | 3 month · $9.74M |
| 2025-06-30 | $0.00 | $64.00K | $1.06B | $527.00K | $-589.48M | $468.28M | 3 month · $9.47M |
| 2025-03-31 | $0.00 | $64.00K | $1.05B | $654.00K | $-512.94M | $535.00M | 3 month · $7.74M |
| 2024-12-31 | $0.00 | $64.00K | $1.04B | $393.00K | $-461.25M | $577.15M | 12 month · $20.80M |
| 2024-09-30 | $0.00 | $55.00K | $705.78M | $1.04M | $-417.82M | $289.06M | 3 month · $5.59M |
| 2024-06-30 | $0.00 | $55.00K | $699.46M | $-450.00K | $-371.19M | $327.87M | 3 month · $4.87M |
| 2024-03-31 | $0.00 | $54.00K | $691.15M | $-173.00K | $-337.49M | $353.54M | 3 month · $4.12M |
| 2023-12-31 | $0.00 | $44.00K | $410.49M | $251.00K | $-309.10M | $101.69M | 12 month · $11.49M |
| 2023-09-30 | $0.00 | (m) | $407.19M | $-75.00K | $-283.45M | $123.71M | 3 month · $2.92M |
| 2023-06-30 | $0.00 | (m) | $403.96M | $-142.00K | $-263.34M | $140.52M | 3 month · $2.68M |
| 2023-03-31 | $0.00 | (m) | $400.85M | $-4.00K | $-243.18M | $157.71M | 3 month · $2.67M |
| 2022-12-31 | $0.00 | $28.00K | $290.22M | $-224.00K | $-213.11M | $76.91M | 12 month · $8.89M |
| 2022-09-30 | $0.00 | (m) | $286.64M | $-279.00K | $-180.67M | $105.72M | 3 month · $2.45M |
| 2022-06-30 | $0.00 | (m) | $277.62M | $-152.00K | $-155.99M | $121.50M | 3 month · $2.02M |
| 2022-03-31 | $0.00 | (m) | $275.55M | $-12.00K | $-141.14M | $134.43M | 3 month · $1.66M |
| 2021-12-31 | $0.00 | (m) | $193.63M | $0.00 | $-124.06M | $69.59M | 12 month · $3.01M |
| 2021-09-30 | (m) | (m) | $192.66M | (m) | $-107.21M | $85.48M | 3 month · $933.00K |
| 2021-06-30 | (m) | (m) | $191.73M | (m) | $-99.60M | $92.16M | 3 month · $713.00K |
| 2021-03-31 | (m) | (m) | $2.85M | (m) | $-96.16M | $-93.32M | 3 month · $404.00K |
| 2020-12-31 | $0.00 | (m) | $2.10M | (m) | $-91.45M | $-89.35M | 12 month · $331.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | $-46.88M | 3 month · $55.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-42.47M | 3 month · $72.00K 6 month · $72.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-38.95M | 3 month · $61.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | $-36.55M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |